PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsEuropean approval for skin cancer drug that could double lifespan

BioNews

European approval for skin cancer drug that could double lifespan

Published 31 January 2013 posted in News and appears in BioNews 646

Author

Dr Louisa Petchey

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The European approval of a new gene-specific drug for an aggressive form of skin cancer marks another step towards an era of personalised medicine. A recent trial showed promising results, with the drug shrinking tumour size and extending life span...

The European approval of a new gene-specific drug for an aggressive form of skin cancer marks another step towards an era of personalised medicine. A recent trial showed promising results, with the drug shrinking tumour size and extending life span.

The drug, which works by targeting a genetic mutation present in the tumours of approximately half of all melanoma patients, comes with its own diagnostic genetic test in order to identify which patients could benefit.

Vemurafenib (Zelboraf) was developed by Roche and according to Hal Barron, chief medical officer and head of product development at the company it 'exemplifies the benefits that [a] personalised approach to medicine can provide for patients, physicians and society'.

Dr Antoni Ribas, a professor of haematology and oncology at the Jonsson Cancer Center at the University of California, Los Angeles, who led the most recent drug trial, agrees. He says the results 'tell us that this drug is having a very big impact, and this changes the way we treat metastatic melanoma'.

Vemurafenib works by switching off the activity of a gene called BRAF, which is normally involved in regulating when a cell divides. When BRAF is mutated, as in some metastatic melanomas, it becomes permanently switched on, leading to excessive cell division and the formation of a tumour.

The trial run by Dr Ribas looked at 132 patients whose tumours all contained this BRAF mutation. The results, published in The New England Journal of Medicine, showed that vemurafenib treatment, while not curing the cancer, shrunk the melanomas 'better than chemotherapy' and extended the median lifespan of patients to 16 months, compared with nine months when using conventional treatment.

This is the first new drug developed for this disease in over a decade, which Roche is taking as a sign that their approach of designing personalised medicines along with diagnostic tests to identify suitable patients is the way forward. But while the drug is promising, there are some concerns.

In the latest trial only 53 percent of patients responded to the drug, despite all carrying the mutation, which has important implications when calculating costs. If this is the case in the general population, this would mean that only around 25 percent of metastatic melanoma patients would benefit. However, according to the authors, this still compares quite favourably to the typical response rate of less than 10 percent for the few alternative treatment options currently available.

In addition, the cancer will eventually become resistant to the drug, and start to grow again. This is currently the major limiting factor associated with many of the cancer drugs targeted at specific mutations.

'We're getting somewhere with these targeted drugs but we have a whole raft of research still to do to address the issue of resistance', says Kate Law, director of clinical and population research at Cancer Research UK.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
24 August 2015 • 2 minutes read

Precision medicine approach effective in lung cancer

by Kirsty Oswald

Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 September 2014 • 2 minutes read

'Personalised' skin cancer drug wins NICE approval

by Dr Lanay Griessner

A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
28 February 2013 • 2 minutes read

DNA decoy drug, first of its kind, trialled in resistant melanoma

by James Brooks

A drug that mimics broken strands of DNA and pushes treatment-resistant cancer cells to autodestruct has produced encouraging results in a first clinical trial. The medicine, DT01, is the forerunner for a new class of drug developed by researchers at the Institut Curie in Paris...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
27 February 2013 • 2 minutes read

Melanoma sequencing reveals genetic effects of sun damage

by Dr Louisa Petchey

Whole genome sequencing of melanoma, the deadliest form of skin cancer, has confirmed the long held belief that greater sun exposure raises cancer risk by increasing the frequency of genetic mutation. The study also identifies one gene, PREX2, that is mutated in 14 percent of cases...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
27 February 2013 • 2 minutes read

Stem cells could shield healthy tissue from chemotherapy

by Dr Antony Starza-Allen

Stem cells transplanted into the brain may offer protection against the side effects of chemotherapy, say US researchers...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 January 2013 • 2 minutes read

UK cancer charity launches project to develop personalised medicines

by Dr Rosie Morley

An initiative has been launched to collect genetic data from NHS cancer patients in the hope of developing new, personalised treatments....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 January 2013 • 2 minutes read

Successful trial of genetic test to guide personalised cancer therapy

by Dr Louisa Petchey

A new genetic test that will help to tailor drugs to cancer patients' individual tumours has been successfully trialled in the US...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 November 2012 • 2 minutes read

Caffeinated suncream gives protection a boost

by Dr Rosie Morley

A new study has found that caffeine could help to block cancer formation in UV-sensitive mice by increasing the likelihood of damaged cells dying after sun exposure. The findings suggest caffeine could help protect against skin cancer by promoting the death of cells with damaged DNA....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 1 minute read

Genetic variation raises melanoma risk in those who tan easily

by Lorna Stewart

Having dark hair and tanning easily does not necessarily make you less likely to develop skin cancer, according to data presented last week at the annual meeting for the American Association for Cancer Research in Denver. Researchers from the University of Pennsylvania, US, found that people who...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Gene link to melanoma in younger women

by Dr Rebecca Robey

US scientists have found a link between a variant in the gene MDM2, called MDM2 SNP309, and the occurrence of melanoma in younger women. The study, published in the journal Clinical Cancer Research, found that MDM2 SNP309 was significantly more common in women who were diagnosed with...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Challenge to compulsory DNA sampling of felony arrestees fails in California

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856